Differential Antigen Processing by Dendritic Cell Subsets in Vivo

By Diana Dudziak, A. Kamphorst, Gordon F Heidkamp, V. R. Buchholz, C. Trumpfheller, S. Yamazaki, C. Cheong, Kang Liu, Han-Woong Lee, Chae Gyu Park and 2 more. Science, 2007

1,537 citations recorded by the source corpus.

Dendritic cells (DCs) process and present self and foreign antigens to induce tolerance or immunity. In vitro models suggest that induction of immunity is controlled by regulating the presentation of antigen, but little is known about how DCs control antigen presentation in vivo. To examine antigen processing and presentation in vivo, we specifically targeted antigens to two major subsets of DCs by using chimeric monoclonal antibodies. Unlike CD8+ DCs that express the cell surface protein CD205, CD8– DCs, which are positive for the 33D1 antigen, are specialized for presentation on major histocompatibility complex (MHC) class II. This difference in antigen processing is intrinsic to the DC subsets and is associated with increased expression of proteins involved in MHC processing.

Subfields: Immunology

View Paper: https://www.semanticscholar.org/paper/2b42da2103646d6ae2d16ba104eed3b34145d0f4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

Citations in the corpus

Immunological mechanisms of vaccination (2011, background): “CD11c + CD11b − CD8α + DCs seem more efficient at cross-presenting antigens to CD8 + T cell”
Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. (2008, background): “As in an earlier study (Dudziak et al., 2007), we found that LCs express more genes related to the MHC class I pathway, and CD14 DCs express more genes related to the MHC class II pathway (data not shown), and such a finding may explain the superior ability of LCs to crosspresent peptides on class I”
IMMUNE TOLERANCE INDUCTION BY APOPTOTIC CELLS REQUIRES CASPASE-DEPENDENT OXIDATION OF HMGB1 (2008, background): “Antigens associated with engulfed dying cells are channeled into the exogenous pathway of class I major histocompatibility complex (MHC) presentation for stimulation of CD8+ T cells (Blachere et al., 2005; Dudziak et al., 2007; Ferguson et al., 2002; Steinman et al., 2003).”
Cancer immunotherapy via dendritic cells (2012, positive): “This could be used to modulate DC function using naked antibodies — for example, by inducing their activation through CD40 — or to link activation signalling with antigen delivery to DCs in vivo using antibodies linked with antigens (known as in vivo DC targeting”
Th17 cells promote cytotoxic T cell activation in tumor immunity (2009, background): “The predominant DCs recruited were CD8a, which are indispensable for cross-presentation of self-antigens in several tissues and in the lung (den Haan and Bevan, 2002; Dudziak et al., 2007; Schnorrer et al., 2006).”
Tolerogenic dendritic cells and the quest for transplant tolerance (2007, background): “Under steady-state conditions antigen presentation by splenic CD8α + DCs leads to T-cell tolerance, whereas under the influence of DC maturation stimuli it leads to T-cell-mediated immunit”
Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209+ dendritic cells for immune T cell areas (2010, background): “The CD8 subset of classical DCs are specialized for cross-presentation (den Haan et al., 2000; Schnorrer et al., 2006; Dudziak et al., 2007; Sancho et al., 2009), but Mo-DCs have not been assessed in vivo.”
Blood monocytes: development, heterogeneity, and relationship with dendritic cells. (2009, background): “Tip-DC: TNF-α and iNOS-producing DC cDCs, are present in all lymphoid organs and can be divided into subsets according to phenotype, location, and function (67).”
The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8α+ dendritic cells (2010, background): “CD11b+ DCs preferentially prime CD4+ T cells and promote humoral immunity (Carter et al., 2006; Dudziak et al., 2007).”
Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8α+ dendritic cells (2010, background): “…products such as CD8, TLR3, CD36, CD103, and nectin-like 2 (Necl2) protein, but lower or undetectable levels of CD11b, TLR7, DCIR2 (also known as 33D1), RIG-I, MDA5, CD11b, and SIRP (Edwards et al., 2003; Galibert et al., 2005; Dudziak et al., 2007; Luber et al., 2010; Shortman and Heath, 2010).”
MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells (2009, background): “DC activation results, therefore, in the enhanced ability to stimulate and polarize T cells in vitro and in vivo (6).”
Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens (2010, background): “Both subsets isolated from blood exhibited similar morphology and phenotype to those previously described (Dzionek et al., 2000; MacDonald et al., 2002; Fig.”